Business Areas
LG Chem helps the people to lead a healthy life by strengthening its R&D competence in Life Sciences.
Life Sciences is the company's new growth engine in the mid to long term goal. The company has secured the differentiated R&D competence and has received the U.S. FDA approval for its new drugs for the first time in Korea.
The company has actively penetrated into the overseas market and has expanded the pipelines for developing new drugs with active investment in R&D. The company is doing its best to become one of the best global pharmaceutical companies.
Sales
0.55KRW trillion
2017
0.57KRW trillion
2018
0.63KRW trillion
2019
  • 1984 Established Pharmaceuticals business division
  • 1991 Developed World’s first4th generation Cephalosporin
  • 2003 1st Korean NCE approved by USA FDA(Factive)
  • 2017 Merged with LG Life Sciences
Division
Primary Drug (PD) Primary Drug (PD)
Specialty Drug(SD) Specialty Drug(SD)
Aesthetic Aesthetic
New Drug Pipeline
New Drug Pipeline: Disease area, Code, Indication, Development stage, Research, Preclinical, clinical, Phase I, Phase II, Phase III, NDA, Remark
Disease area Code Indication Development stage Remark
Research Preclinical Development stage NDA
Phase I Phase II Phase III
Metabolic Diseases
LR19052
Diabetes
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding  
Zemiglo® combination drug (Korea)
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding NDA Proceeding
LR19051
Diabetes
 Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding  
Zemiglo® combination drug (Thailand)
Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19123
Diabetes
 Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19074
Gout
 Research complete Preclinical complete Phase I Proceeding Phase II Before proceeding Phase III Before proceeding  
US
Research complete Preclinical Proceeding Phase I Proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19021
Obesity
 Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
US
Research complete Preclinical Proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19020
Obesity
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19156
Obesity
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR20056
NASH (nonalcoholic steatohepatitis)
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
In Partnership with transthera
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19018
NASH (nonalcoholic steatohepatitis)
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR20010
NASH (nonalcoholic steatohepatitis)
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19131
NASH (nonalcoholic steatohepatitis)
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
Oncology
LR19127
Oncology
 Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
In Partnership with (US) cue
Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19125
Oncology
 Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
In Partnership with (Europe ) pdc
Research complete Preclinical complete Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR20011
Oncology
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
In Partnership with (US) genomeCompany
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR20009
Oncology
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19129
Oncology
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
In Partnership with transthera
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19023
Oncology
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR19155
Oncology
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
LR20018
Oncology
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Proceeding
Immunology
LR19055
Autoimmune Disease
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding  
Humira® biosimilar
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding NDA Proceeding
LR19025
Degenerative Disease
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
In Partnership with medi post
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Before proceeding
LR19024
Degenerative Disease
 Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding  
Research Proceeding Preclinical Before proceeding Phase I Before proceeding Phase II Before proceeding Phase III Before proceeding NDA Before proceeding
Vaccine Pipeline
New Drug Pipeline: Disease area, Code, Indication, Development stage, Research, Preclinical, clinical, Phase I, Phase II, Phase III, NDA, Remark
Disease area Code Indication Development stage Remark
Research Preclinical Development stage NDA
Phase I Phase II Phase III
Vaccine
LR19113
Polio
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Funded by BMGF* / Received export license from MFDS**
Research complete Preclinical complete Phase I complete Phase II complete Phase III Before proceeding NDA Proceeding
LR19122
6-in-1 (Diphtheriae, Tetanus, Pertussis, Hepatitis B, Meningitis, Polio)
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Funded by BMGF*
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding NDA Proceeding
*BMGF: Bill & Melinda Gates Foundation / **MFDS: Ministry of Food and Drug Safety (Korea)
Aesthetics Pipeline
New Drug Pipeline: Disease area, Code, Indication, Development stage, Research, Preclinical, clinical, Phase I, Phase II, Phase III, NDA, Remark
Disease area Code Indication Development stage Remark
Research Preclinical Development stage NDA
Phase I Phase II Phase III
Cosmetic plastic filler
LR19093
Facial wrinkles, etc.
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Medical Device
(China)
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding NDA Proceeding
LR19153
Facial wrinkles, etc.
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Medical Device
(Europe)
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding NDA Proceeding
LR20008
New fillers
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding NDA Proceeding
botulinum toxin
LR20023
Frown lines
 Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding
In Partnership with pharma Research Bio
Research complete Preclinical complete Phase I complete Phase II complete Phase III Proceeding NDA Proceeding
Core Products
Eutropin Eutropin
Hyruan One Hyruan One
Zemiglo Zemimet SR Tab Zemiglo / Zemimet SR Tab
Eucept Eucept
YVOIRE YVOIRE
Press Releases
LG Chem to contribute to global polio eradication with Eupolio, the first Sabin Inactivated Polio Vaccine to receive WHO prequalification 2021.01.07
LG Chem to contribute to global polio eradication with Eupolio, the first Sabin Inactivated Polio Vaccine to receive WHO prequalification 2021.01.07
LG Chem's new diabetes drug 'Zemiglo' has reached the highest sales among domestically developed drugs 2020.12.15
more
Video
Select Opening of a Global Innovation Center Opening of a Global Innovation Center